Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 2/20 | 0.32 |
| ▸ | PPARA | Q07869 | 2/20 | 0.32 |
| ▸ | CCR2 | P41597 | 1/20 | 0.32 |
| ▸ | KMO | O15229 | 2/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29574363 | 1.00 | TDP1 (0.38) | TDP1MAPK1CYP3A4HPGDALDH1A1 | |
| SCHEMBL1569005 | 0.86 | TDP1 (0.39) | TDP1MAPK1CYP3A4HPGDALDH1A1 | |
| SCHEMBL10316536 | 0.81 | TDP1 (0.42) | TDP1MAPK1CYP3A4HPGDALDH1A1 | |
| SCHEMBL30111366 | 0.81 | TDP1 (0.42) | TDP1MAPK1CYP3A4HPGDALDH1A1 | |
| SCHEMBL6596126 | 0.80 | HTR2B (0.33) | TDP1CYP3A4HPGDALDH1A1KMT2A | |
| SCHEMBL30298623 | 0.80 | HTR2B (0.33) | TDP1CYP3A4HPGDALDH1A1KMT2A | |
| SCHEMBL29862788 | 0.79 | TDP1 (0.45) | TDP1MAPK1CYP3A4HPGDALDH1A1 | |
| SCHEMBL76596 | 0.79 | ALDH1A1 (0.40) | TDP1MAPK1CYP3A4HPGDALDH1A1 | |
| SCHEMBL29533142 | 0.79 | ALDH1A1 (0.40) | TDP1MAPK1CYP3A4HPGDALDH1A1 | |
| SCHEMBL227614 | 0.79 | TDP1 (0.45) | TDP1MAPK1CYP3A4HPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 198 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-57058672-A | — | — | None | — | — | JP | disclosed |
| EP-4713378-A1 | ESTERIFIED ETHANOLAMINES FOR PREPARING ISOCYANURATE POLYMERS | Covestro Deutschland AG (DE) | 2026-03-25 | — | — | EP | disclosed |
| EP-3774961-B1 | ADDUCTS OF AMINE CATALYSTS FOR PRODUCING ISOCYANURATE POLYMERS | COVESTRO DEUTSCHLAND AG (DE) | 2025-01-15 | — | — | EP | disclosed |
| WO-2024236000-A1 | ESTERIFIED ETHANOLAMINES FOR PREPARING ISOCYANURATE POLYMERS | COVESTRO DEUTSCHLAND AG (DE) | 2024-11-21 | — | — | WO | disclosed |
| EP-4464727-A1 | ESTERIFIED ETHANOLAMINES FOR THE PREPARATION OF ISOCYANURATE POLYMERS | Covestro Deutschland AG (DE) | 2024-11-20 | — | — | EP | disclosed |
| US-12145927-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-11-19 | — | — | US | disclosed |
| CN-118955409-A | Cardiac sarcomere inhibitors | 赛特凯恩蒂克公司 | 2024-11-15 | — | — | CN | disclosed |
| US-12059420-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-08-13 | — | — | US | disclosed |
| CN-112867539-B | Cardiac sarcomere inhibitors | 赛特凯恩蒂克公司 | 2024-08-06 | — | — | CN | disclosed |
| US-20240150515-A1 | Low Viscosity Catalyst Compositions for Producing Isocyanurate Polymers | COVESTRO DEUTSCHLAND AG (DE) | 2024-05-09 | — | — | US | disclosed |
| WO-1987003873-A1 | HERBICIDAL 1-ARYL-4-SUBSTITUTED-1,4-DIHYDRO-5H-TETRAZOL-5-ONES AND SULFUR ANALOGS THEREOF | FMC CORPORATION (US) | 1987-07-02 | — | — | WO | disclosed |
| US-4582948-A | VAPOR PHASE CHLORO-DENITRATION REACTION | OCCIDENTAL CHEMICAL CORPORATION (US) | 1986-04-15 | — | — | US | disclosed |
| US-4564639-A | INSECTICIDES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1986-01-14 | — | — | US | disclosed |
| EP-0159388-A2 | Preparation of nuclear chlorinated compounds | OCCIDENTAL CHEMICAL CORPORATION (US) | 1985-10-30 | — | — | EP | disclosed |
| EP-0088343-B1 | UREA DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1985-07-03 | — | — | EP | disclosed |
| US-4470930-A | Preparation of nuclear chlorinated aromatic compounds | OCCIDENTAL CHEMICAL CORPORATION (US) | 1984-09-11 | — | — | US | disclosed |
| EP-0088343-A2 | Urea derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1983-09-14 | — | — | EP | disclosed |
| JP-S5758672-A | SUBSTITUTED PHENYLHYDANTION DERIVATIVE, ITS PREPARATION, AND HERBICIDE COMPRISING IT AS ACTIVE IN GREDIENT | SUMITOMO CHEM CO LTD | 1982-04-08 | — | — | JP | disclosed |
| US-4220465-A | PREEMERGENCE OR POSTEMERGENCE HERBICIDES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1980-09-02 | — | — | US | disclosed |
| US-4179276-A | HERBICIDES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1979-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12059420-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | IDO1, IDO2, INMT | TDP1 1045/4885MAPK1 1947/4885CYP3A4 570/4885 |
| US-12145927-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | IDO1, IDO2, INMT | TDP1 1033/4885MAPK1 1737/4885CYP3A4 506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.